|
1
|
Hasserjian RP: Myelodysplastic syndrome
updated. Pathobiology. 86:7–13. 2019.
|
|
2
|
Haferlach T: The molecular pathology of
myelodysplastic syndrome. Pathobiology. 86:24–29. 2019.
|
|
3
|
Yan X, Lai B, Zhou X, Yang S, Ge Q, Zhou
M, Shi C, Xu Z and Ouyang G: The differential expression of CD47
may be related to the pathogenesis from myelodysplastic syndromes
to acute myeloid leukemia. Front Oncol. 12:8729992022.
|
|
4
|
Menssen AJ and Walter MJ: Genetics of
progression from MDS to secondary leukemia. Blood. 136:50–60.
2020.
|
|
5
|
Rankin EB, Narla A, Park JK, Lin S and
Sakamoto KM: Biology of the bone marrow microenvironment and
myelodysplastic syndromes. Mol Genet Metab. 116:24–28. 2015.
|
|
6
|
Liu W, Teodorescu P, Halene S and Ghiaur
G: The coming of age of preclinical models of MDS. Front Oncol.
12:8150372022.
|
|
7
|
Venney D, Mohd-Sarip A and Mills KI: The
impact of epigenetic modifications in myeloid malignancies. Int J
Mol Sci. 22:50132021.
|
|
8
|
Shukron O, Vainstein V, Kündgen A, Germing
U and Agur Z: Analyzing transformation of myelodysplastic syndrome
to secondary acute myeloid leukemia using a large patient database.
Am J Hematol. 87:853–860. 2012.
|
|
9
|
Zhang Z, Richmond A and Yan C:
Immunomodulatory properties of PI3K/AKT/mTOR and MAPK/MEK/ERK
inhibition augment response to immune checkpoint blockade in
melanoma and triple-negative breast cancer. Int J Mol Sci.
23:73532022.
|
|
10
|
Fu NJ, Xi RY, Shi XK, Li RZ, Zhang ZH, Li
LY, Zhang GL and Wang F: Hexachlorophene, a selective SHP2
inhibitor, suppresses proliferation and metastasis of KRAS-mutant
NSCLC cells by inhibiting RAS/MEK/ERK and PI3K/AKT signaling
pathways. Toxicol Appl Pharmacol. 441:1159882022.
|
|
11
|
Peng M, Fan S, Li J, Zhou X, Liao Q, Tang
F and Liu W: Programmed death-ligand 1 signaling and expression are
reversible by lycopene via PI3K/AKT and Raf/MEK/ERK pathways in
tongue squamous cell carcinoma. Genes Nutr. 17:32022.
|
|
12
|
Zebisch A, Czernilofsky AP, Keri G,
Smigelskaite J, Sill H and Troppmair J: Signaling through
RAS-RAF-MEK-ERK: From basics to bedside. Curr Med Chem. 14:601–623.
2007.
|
|
13
|
Liang S, Zhou X, Cai D, Rodrigues-Lima F,
Chi J and Wang L: Network pharmacology and experimental validation
reveal the effects of chidamide combined with aspirin on acute
myeloid leukemia-myelodysplastic syndrome cells through PI3K/AKT
pathway. Front Cell Dev Biol. 9:6859542021.
|
|
14
|
Akutagawa J, Hua ng TQ, Epstein I, Chang
T, Quirindongo-Crespo M, Cottonham CL, Dail M, Slusher BS, Friedman
LS, Sampath D and Braun BS: Targeting the PI3K/Akt pathway in
murine MDS/MPN driven by hyperactive Ras. Leukemia. 30:1335–1343.
2016.
|
|
15
|
Chung E, Hsu CL and Kondo M: Constitutive
MAP kinase activation in hematopoietic stem cells induces a
myeloproliferative disorder. PLoS One. 6:e283502011.
|
|
16
|
Gonzalez-Lugo JD, Chakraborty S, Verma A
and Shastri A: The evolution of epigenetic therapy in
myelodysplastic syndromes and acute myeloid leukemia. Semin
Hematol. 58:56–65. 2021.
|
|
17
|
Hojfeldt JW, Agger K and Helin K: Histone
lysine demethylases as targets for anticancer therapy. Nat Rev Drug
Discov. 12:917–930. 2013.
|
|
18
|
Ruan XF, Li YJ, Ju CW, Shen Y, Lei W, Chen
C, Li Y, Yu H, Liu YT, Kim IM, et al: Exosomes from Suxiao Jiuxin
pill-treated cardiac mesenchymal stem cells decrease H3K27
demethylase UTX expression in mouse cardiomyocytes in vitro. Acta
Pharmacol Sin. 39:579–586. 2018.
|
|
19
|
Rizk M, Rizq O, Oshima M, Nakajima-Takagi
Y, Koide S, Saraya A, Isshiki Y, Chiba T, Yamazaki S, Ma A, et al:
Akt inhibition synergizes with polycomb repressive complex 2
inhibition in the treatment of multiple myeloma. Cancer Sci.
110:3695–3707. 2019.
|
|
20
|
Ferraro A, Mourtzoukou D, Kosmidou V,
Avlonitis S, Kontogeorgos G, Zografos G and Pintzas A: EZH2 is
regulated by ERK/AKT and targets integrin alpha2 gene to control
epithelial-mesenchymal transition and anoikis in colon cancer
cells. Int J Biochem Cell Biol. 45:243–254. 2013.
|
|
21
|
Zhang TJ, Xu ZJ, Gu Y, Wen XM, Ma JC,
Zhang W, Deng ZQ, Leng JY, Qian J, Lin J and Zhou JD:
Identification and validation of prognosis-related DLX5 methylation
as an epigenetic driver in myeloid neoplasms. Clin Transl Med.
10:e292020.
|
|
22
|
Zheng Z, Li L, Li G, Zhang Y, Dong C, Ren
F, Chen W and Ma Y: EZH2/EHMT2 histone methyltransferases inhibit
the transcription of DLX5 and promote the transformation of
myelodysplastic syndrome to acute myeloid leukemia. Front Cell Dev
Biol. 9:6197952021.
|
|
23
|
Arber DA, Orazi A, Hasserjian R, Thiele J,
Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M and Vardiman JW:
The 2016 revision to the World Health Organization classification
of myeloid neoplasms and acute leukemia. Blood. 127:2391–2405.
2016.
|
|
24
|
You Y, Niu Y, Zhang J, Huang S, Ding P,
Sun F and Wang X: U0126: Not only a MAPK kinase inhibitor. Front
Pharmacol. 13:9270832022.
|
|
25
|
Xu CN, Kong LH, Ding P, Liu Y, Fan ZG, Gao
EH, Yang J and Yang LF: Melatonin ameliorates pressure
overload-induced cardiac hypertrophy by attenuating Atg5-dependent
autophagy and activating the Akt/mTOR pathway. Biochim Biophys Acta
Mol Basis Dis. 1866:1658482020.
|
|
26
|
Guirguis AA, Slape CI, Failla LM, Saw J,
Tremblay CS, Powell DR, Rossello F, Wei A, Strasser A and Curtis
DJ: PUMA promotes apoptosis of hematopoietic progenitors driving
leukemic progression in a mouse model of myelodysplasia. Cell Death
Differ. 23:1049–1059. 2016.
|
|
27
|
Estey E, Hasserjian RP and Döhner H:
Distinguishing AML from MDS: A fixed blast percentage may no longer
be optimal. Blood. 139:323–332. 2022.
|
|
28
|
Zatroch KK, Knight CG, Reimer JN and Pang
DS: Refinement of intraperitoneal injection of sodium pentobarbital
for euthanasia in laboratory rats (Rattus norvegicus). BMC Vet Res.
13:602017.
|
|
29
|
Geng Y, Wu W, Zhou L, Li J, Geng Y and
Yang Y: Synergistic effects of LY294002 and ABT199 on the cell
cycle in K562, HL60 and KG1a cells. Oncol Rep. 45:972021.
|
|
30
|
Wang C, Wang K, Li SF, Song SJ, Du Y, Niu
RW, Qian XW, Peng XQ and Chen FH: 4-Amino-2-trifluoromethyl-phenyl
retinate induced differentiation of human myelodysplastic syndromes
SKM-1 cell lines by up-regulating DDX23. Biomed Pharmacother.
123:1097362020.
|
|
31
|
Zhou W, Xu S, Ying Y, Zhou R and Chen X:
Resveratrol suppresses growth and migration of myelodysplastic
cells by inhibiting the expression of elevated cyclin D1 (CCND1).
DNA Cell Biol. 36:966–975. 2017.
|
|
32
|
Dagdemir A, Durif J, Ngollo M, Bignon YJ
and Bernard-Gallon D: Histone lysine trimethylation or acetylation
can be modulated by phytoestrogen, estrogen or anti-HDAC in breast
cancer cell lines. Epigenomics. 5:51–63. 2013.
|
|
33
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
|
|
34
|
Trivedi G, Inoue D and Zhang L: Targeting
low-risk myelodysplastic syndrome with novel therapeutic
strategies. Trends Mol Med. 27:990–999. 2021.
|
|
35
|
Yue Y, Wang Y, He Y, Yang S, Chen Z, Wang
Y, Xing S, Shen C, Amin HM, Wu D and Song YH: Reversal of
bortezomib resistance in myelodysplastic syndrome cells by MAPK
inhibitors. PLoS One. 9:e909922014.
|
|
36
|
Yin J, Li X, Zhang Z, Luo X, Wang L and
Liu L: SPAG6 silencing induces apoptosis in the myelodysplastic
syndrome cell line SKM-1 via the PTEN/PI3K/AKT signaling pathway
in vitro and in vivo. Int J Oncol. 53:297–306.
2018.
|
|
37
|
Lee P, Yim R, Yung Y, Chu HT, Yip PK and
Gill H: Molecular targeted therapy and immunotherapy for
myelodysplastic syndrome. Int J Mol Sci. 22:102322021.
|
|
38
|
Wheeler EC, Vora S, Mayer D, Kotini AG,
Olszewska M, Park SS, Guccione E, Teruya-Feldstein J, Silverman L,
Sunahara RK, et al: Integrative RNA-omics discovers GNAS
alternative splicing as a phenotypic driver of splicing
factor-mutant neoplasms. Cancer Discov. 12:836–855. 2022.
|
|
39
|
Lin S, Li J, Zhou W, Qian W, Wang B and
Chen Z: BIIB021, an Hsp90 inhibitor, effectively kills a
myelodysplastic syndrome cell line via the activation of caspases
and inhibition of PI3K/Akt and NF-κB pathway proteins. Exp Ther
Med. 7:1539–1544. 2014.
|
|
40
|
Lin YW, Slape C, Zhang Z and Aplan PD:
NUP98-HOXD13 transgenic mice develop a highly penetrant, severe
myelodysplastic syndrome that progresses to acute leukemia. Blood.
106:287–295. 2005.
|
|
41
|
Maiti A, Naqvi K, Kadia TM, Borthakur G,
Takahashi K, Bose P, Daver NG, Patel A, Alvarado Y, Ohanian M, et
al: Phase II trial of MEK inhibitor binimetinib (MEK162) in
RAS-mutant acute myeloid leukemia. Clin Lymphoma Myeloma Leuk.
19:142–148.e1. 2019.
|
|
42
|
Ricciardi MR, Scerpa MC, Bergamo P,
Ciuffreda L, Petrucci MT, Chiaretti S, Tavolaro S, Mascolo MG,
Abrams SL, Steelman LS, et al: Therapeutic potential of MEK
inhibition in acute myelogenous leukemia: Rationale for 'vertical'
and 'lateral' combination strategies. J Mol Med (Berl).
90:1133–1144. 2012.
|
|
43
|
Ragon BK, Odenike O, Baer MR, Stock W,
Borthakur G, Patel K, Han L, Chen H, Ma H, Joseph L, et al: Oral
MEK 1/2 inhibitor trametinib in combination with AKT inhibitor
GSK2141795 in patients with acute myeloid leukemia with RAS
mutations: A phase II study. Clin Lymphoma Myeloma Leuk.
19:431–440.e13. 2019.
|
|
44
|
Täger M, Horn S, Latuske E, Ehm P, Schaks
M, Nalaskowski M, Fehse B, Fiedler W, Stocking C, Wellbrock J and
Jücker M: SHIP1, but not an AML-derived SHIP1 mutant, suppresses
myeloid leukemia growth in a xenotransplantation mouse model. Gene
Ther. 24:749–753. 2017.
|
|
45
|
Lin L, Que Y, Lu P, Li H, Xiao M, Zhu X
and Li D: Chidamide inhibits acute myeloid leukemia cell
proliferation by lncRNA VPS9D1-AS1 downregulation via MEK/ERK
signaling pathway. Front Pharmacol. 11:5696512020.
|
|
46
|
Riquelme E, Behrens C, Lin HY, Simon G,
Papadimitrakopoulou V, Izzo J, Moran C, Kalhor N, Lee JJ, Minna JD
and Wistuba II: Modulation of EZH2 expression by MEK-ERK or
PI3K-AKT signaling in lung cancer is dictated by different KRAS
oncogene mutations. Cancer Res. 76:675–685. 2016.
|
|
47
|
Yamagishi M, Hori M, Fujikawa D, Ohsugi T,
Honma D, Adachi N, Katano H, Hishima T, Kobayashi S, Nakano K, et
al: Targeting excessive EZH1 and EZH2 activities for abnormal
histone methylation and transcription network in malignant
lymphomas. Cell Rep. 29:2321–2337.e7. 2019.
|
|
48
|
Rejlova K, Musilova A, Kramarzova KS,
Zaliova M, Fiser K, Alberich-Jorda M, Trka J and Starkova J: Low
HOX gene expression in PML-RARα-positive leukemia results from
suppressed histone demethylation. Epigenetics. 13:73–84. 2018.
|
|
49
|
Agger K, Cloos PA, Christensen J, Pasini
D, Rose S, Rappsilber J, Issaeva I, Canaani E, Salcini AE and Helin
K: UTX and JMJD3 are histone H3K27 demethylases involved in HOX
gene regulation and development. Nature. 449:731–734. 2007.
|
|
50
|
Zheng L, Zhai Y, Li N, Ma F, Zhu H, Du X,
Li G and Hua J: The modification of Tet1 in male germline stem
cells and interact with PCNA, HDAC1 to promote their self-renewal
and proliferation. Sci Rep. 6:374142016.
|
|
51
|
Kosalai ST, Morsy MHA, Papakonstantinou N,
Mansouri L, Stavroyianni N, Kanduri C, Stamatopoulos K, Rosenquist
R and Kanduri M: EZH2 upregulates the PI3K/AKT pathway through
IGF1R and MYC in clinically aggressive chronic lymphocytic
leukaemia. Epigenetics. 14:1125–1140. 2019.
|
|
52
|
Zitzmann K, Rüden J, Brand S, Göke B,
Lichtl J, Spöttl G and Auernhammer CJ: Compensatory activation of
Akt in response to mTOR and Raf inhibitors-a rationale for
dual-targeted therapy approaches in neuroendocrine tumor disease.
Cancer Lett. 295:100–109. 2010.
|
|
53
|
Turke AB, Song Y, Costa C, Cook R, Arteaga
CL, Asara JM and Engelman JA: MEK inhibition leads to PI3K/AKT
activation by relieving a negative feedback on ERBB receptors.
Cancer Res. 72:3228–3237. 2012.
|
|
54
|
Wu YL, Maachani UB, Schweitzer M, Singh R,
Wang M, Chang R and Souweidane MM: Dual inhibition of PI3K/AKT and
MEK/ERK pathways induces synergistic antitumor effects in diffuse
intrinsic pontine glioma cells. Transl Oncol. 10:221–228. 2017.
|
|
55
|
Cao Z, Liao Q, Su M, Huang K, Jin J and
Cao D: AKT and ERK dual inhibitors: The way forward? Cancer Lett.
459:30–40. 2019.
|
|
56
|
Ramakrishnan V, Kimlinger T, Haug J,
Painuly U, Wellik L, Halling T, Rajkumar SV and Kumar S:
Anti-myeloma activity of Akt inhibition is linked to the activation
status of PI3K/Akt and MEK/ERK pathway. PLoS One. 7:e500052012.
|
|
57
|
Liu L, Chen J, Cao M, Wang J and Wang S:
NO donor inhibits proliferation and induces apoptosis by targeting
PI3K/AKT/mTOR and MEK/ERK pathways in hepatocellular carcinoma
cells. Cancer Chemother Pharmacol. 84:1303–1314. 2019.
|
|
58
|
Xu F, Li X, Wu L, Zhang Q, Yang R, Yang Y,
Zhang Z, He Q and Chang C: Overexpression of the EZH2, RING1 and
BMI1 genes is common in myelodysplastic syndromes: Relation to
adverse epigenetic alteration and poor prognostic scoring. Ann
Hematol. 90:643–653. 2011.
|
|
59
|
Yu SH, Zhu KY, Chen J, Liu XZ, Xu PF,
Zhang W, Yan L, Guo HZ and Zhu J: JMJD3 facilitates C/EBPβ-centered
transcriptional program to exert oncorepressor activity in AML. Nat
Commun. 9:33692018.
|
|
60
|
Mochizuki-Kashio M, Aoyama K, Sashida G,
Oshima M, Tomioka T, Muto T, Wang C and Iwama A: Ezh2 loss in
hematopoietic stem cells predisposes mice to develop heterogeneous
malignancies in an Ezh1-dependent manner. Blood. 126:1172–1183.
2015.
|
|
61
|
Wu B, Pan X, Chen X, Chen M, Shi K, Xu J,
Zheng J, Niu T, Chen C, Shuai X and Liu Y: Epigenetic drug library
screening identified an LSD1 inhibitor to target UTX-deficient
cells for differentiation therapy. Signal Transduct Target Ther.
4:112019.
|
|
62
|
Fujii S, Tokita K, Wada N, Ito K, Yamauchi
C, Ito Y and Ochiai A: MEK-ERK pathway regulates EZH2
overexpression in association with aggressive breast cancer
subtypes. Oncogene. 30:4118–4128. 2011.
|
|
63
|
Jiang Q, Huang X, Hu X, Shan Z, Wu Y, Wu G
and Lei L: Histone demethylase KDM6A promotes somatic cell
reprogramming by epigenetically regulating the PTEN and IL-6 signal
pathways. Stem Cells. 38:960–972. 2020.
|
